The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy

被引:16
作者
Azzariti, Amalia [1 ]
Porcelli, Letizia [1 ]
Quatrale, Anna Elisa [1 ]
Silvestris, Nicola [2 ]
Paradiso, Angelo [1 ]
机构
[1] Natl Canc Inst Giovanni Paolo II, Clin Expt Oncol Lab, I-70124 Bari, Italy
[2] Natl Canc Inst Giovanni Paolo II, Med & Expt Oncol Unit, I-70124 Bari, Italy
关键词
Cancer; CYP450; Glycoprotein P; platinum compounds; resistance to chemotherapy; tyrosine kinase inhibitors; INTESTINAL DRUG ABSORPTION; MDR1 GENE POLYMORPHISMS; GROWTH-FACTOR RECEPTOR; BLOOD-BRAIN-BARRIER; CYTOCHROME-P450; 3A; IMMUNOHISTOCHEMICAL LOCALIZATION; HEPATOCELLULAR-CARCINOMA; ORAL BIOAVAILABILITY; 1ST-PASS METABOLISM; TISSUE DISTRIBUTION;
D O I
10.2174/138920011798357042
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The relationship between CYP450 and P-gp occurs at different levels. It is known that certain substrates of P-gp undergo metabolic transformations by various CYP450 isoforms; in addition some of them demonstrated to be activators of both P-gp and CYP450. The majority of such compounds are well-known chemotherapeutics, therefore the purpose of this review is to clarify whether there is a relationship between the simultaneous modulation of CYP450 and P-gp and the onset of drug resistance in tumors treatment. Here, we discuss the biological aspects of the topic in relation to the various tissues distribution of CYP450 and P-gp, the recent findings regarding the ability of some chemotherapeutics in modulating both P-gp and CYP450, whether this modulation is ultimately responsible for the onset of drug resistance in cancer treatment and the promising role of gene polymorphisms in determining the interindividual variability in drug responses in clinical practice.
引用
收藏
页码:713 / 721
页数:9
相关论文
共 111 条
[1]   The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa,™, ZD1839) [J].
Azzariti, A ;
Xu, HM ;
Porcelli, L ;
Paradiso, A .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (01) :135-144
[2]  
Azzariti A., 2008, MULTI DRUG RESISTANC, V37/661, P1
[3]   Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells [J].
Azzariti, Amalia ;
Porcelli, Letizia ;
Gatti, Giuliana ;
Nicolin, Angelo ;
Paradiso, Angelo .
BIOCHEMICAL PHARMACOLOGY, 2008, 75 (05) :1035-1044
[4]  
Azzariti A, 2006, WORLD J GASTROENTERO, V12, P5140
[5]   Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences [J].
Azzariti, Amalia ;
Porcelli, Letizia ;
Simone, Grazia M. ;
Quatrale, Anna E. ;
Colabufo, Nicola A. ;
Berardi, Francesco ;
Perrone, Roberto ;
Zucchetti, Massimo ;
D'Incalci, Maurizio ;
Xu, Jian Ming ;
Paradiso, Angelo .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (02) :335-346
[6]  
Bardelmeijer HA, 2002, CANCER RES, V62, P6158
[7]   Unmasking the dynamic interplay between efflux transporters and metabolic enzymes [J].
Benet, LZ ;
Cummins, CL ;
Wu, CY .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 277 (1-2) :3-9
[8]   SXR, a novel steroid and xenobiotic-sensing nuclear receptor [J].
Blumberg, B ;
Sabbagh, W ;
Juguilon, H ;
Bolado, J ;
van Meter, CM ;
Ono, ES ;
Evans, RM .
GENES & DEVELOPMENT, 1998, 12 (20) :3195-3205
[9]   Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide [J].
Bray, J. ;
Sludden, J. ;
Griffin, M. J. ;
Cole, M. ;
Verrill, M. ;
Jamieson, D. ;
Boddy, A. V. .
BRITISH JOURNAL OF CANCER, 2010, 102 (06) :1003-1009
[10]   Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model [J].
Cao, Xianhua ;
Gibbs, Seth T. ;
Fang, Lanyan ;
Miller, Heather A. ;
Landowski, Christopher P. ;
Shin, Ho-Chul ;
Lennernas, Hans ;
Zhong, Yanqiang ;
Amidon, Gordon L. ;
Yu, Lawrence X. ;
Sun, Duxin .
PHARMACEUTICAL RESEARCH, 2006, 23 (08) :1675-1686